Device Week, 25 June 2021 – Major SPAC; Novel Heart Pump; And Breakthrough Device Designation

In this edition of Device Week, Medtech Insight's UK-based reporter Barnaby Pickering provides an insight into Procyrion’s novel device for decongesting cardiorenal syndrome patients. US Commercial and R&D manager, Reed Miller, highlights details on Pear Therapeutics’ recent SPAC acquisition, and managing editor, Marion Webb, discusses two companies that received types of approval for novel devices.

Medtech Insight articles discussed in this week’s episode:

Onward Secures FDA Breakthrough Designation To Improve Movement, Quality Of Life After Spinal Cord Injuries

Start-Up Spotlight: Procyrion Trials Novel Device To Tackle Cardiorenal Syndrome